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Abstract
Introduction and hypothesis Treatment options for women
with stress urinary incontinence (SUI) have limitations. We
hypothesized that multimodal vaginal toning therapy would
improve bladder symptoms and quality of life in women with
postpartum SUI and sexual function complaints.
Methods Patients self-administered 24 sessions ofmultimodal
vaginal toning therapy lasting 10 min each over 50 days.
Outcomes included 1-h pad weight test, Urogenital Distress
Inventory Short Form (UDI-6), Incontinence Impact
Questionnaire-Short Form (IIQ-7), Female Sexual Distress
Scale-Revised 2005 (FSDS-R), Female Sexual Function
Index (FSFI), pelvic floor muscle strength, patient satisfac-
tion, and adverse events.
Results Of the 55 patients enrolled (safety population), 48
completed the study per-protocol (PP population). A total of
38 (79%) patients had a positive 1-h pad weight test at base-
line. In this group, urine leakage was moderate or severe in
82% of patients at baseline, but in only 18% after treatment.
Treatment success was 84%, defined as >50% improvement
in pad weight relative to baseline. In the PP population, mean
UDI-6 score improved by 50% (p<0.001) and IIQ-7 score
improved by 69% (p<0.001). Sexual function quality of life
improved by 54% for FSDS-R and 15% for FSFI (both
p< 0.001). Pelvic floor muscle strength significantly im-
proved (p<0.001). Patient satisfaction with therapy was re-
ported in 83% of patients. In the safety population, 2 (3.6%)
adverse events were reported—1 urinary tract infection and 1
report of discomfort due to excessive warmth.
Conclusions Multimodal vaginal toning therapy yields clini-
cally meaningful improvements in bladder symptoms, pelvic
floor muscle strength, and quality of life in women with SUI.
Keywords Female sexual dysfunction . Low-level light .
Postpartum . Stress urinary incontinence . Vaginal toning
Introduction
Urinary incontinence is a prevalent condition affecting wom-
en of all ages that is responsible for almost $20 billion in costs
in the USA [1]. Approximately 35% of women have experi-
enced urinary incontinence, with stress urinary incontinence
(SUI) the most common subtype [2]. SUI is characterized by
involuntary urine leakage on effort or exertion, or during
sneezing or coughing. Primary risk factors include pregnancy,
childbirth, hysterectomy, obesity, older age, and family histo-
ry. SUI has significant negative influences on physical, psy-
chological, and social wellbeing in affected patients. Strong
associations between SUI and sexual dysfunction have also
been reported [3]. In addition to the impact of this condition
on the patient, SUI is also financially burdensome. Lifetime
medical costs are double in women with SUI compared with
women without the condition [4, 5], resulting in annual direct
costs of $5,600 and indirect costs of $4,200 per patient [4].
The physical and economic burden of SUI in women may be
underestimated as up to 50% of patients fail to report their
symptoms to a healthcare provider [6].
Initial conservative measures for SUI typically consist of
lifestyle modifications such as caffeine reduction, fluid intake
reduction, and weight loss in obese individuals. Pelvic floor
muscle training, continence support pessaries, and
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pharmacotherapy may be prescribed if initial conservative
measures fail to alleviate symptoms. However, the therapeutic
efficacy of these strategies is limited owing to poor long-term
patient compliance [7]. In patients who are unresponsive to
conservative measures, surgical intervention such as
midurethral sling or open colposuspension may be offered.
Although initial surgical outcomes are generally positive, op-
erative complications such as bladder perforation, voiding
dysfunction, and neurological symptoms are known risks
[8]. Additionally, surgical efficacy diminishes over time such
that a repeat procedure is necessary in 5–10% of patients after
5 years [9]. In those who undergo revision surgery, inconti-
nence cure rates are lower compared with primary procedures
[10]. Even in patients who achieve satisfactory long-term res-
olution of bladder symptoms, SUI surgery does not improve
sexual function [11]. As patients with SUI also have high rates
of sexual dysfunction [12], the overall benefit of SUI surgery
to the patient is debatable.
In accordance with American Congress of Obstetricians
and Gynecologists guidance [13], nonsurgical treatments
should be initially attempted in women for SUI, with more
invasive surgical therapies reserved only for those who are
nonresponsive to conservative measures. Given the limited
effectiveness of traditional conservative treatments and the
risks and limited durability of surgery, there is a clear need
for non-invasive therapies that are safe and result in clinically
meaningful reductions in SUI symptoms with associated im-
provements in sexual function. We hypothesized that multi-
modal vaginal toning therapy would improve bladder symp-
toms and quality of life (QoL) in women with postpartum SUI
and sexual function complaints.
Materials and methods
Study design
This was a prospective case series conducted at a single OB/
GYN clinic (Seattle OB/GYN Group, Seattle, WA, USA). All
patients provided informed consent before study participation
and the research was approved by the Western Institutional
Review Board (Puyallup, WA, USA).
Patient enrollment
Consecutive patients were evaluated for study eligibility by
the assessment of inclusion and exclusion criteria, medical
history, and physical examination. Eligible patients were
women aged 30 to 59 years; self-reported symptoms of SUI;
postpartum with one or more vaginal births; painful inter-
course with male partner; and dissatisfaction with intercourse.
Main exclusion criteria were active sexually transmitted dis-
ease or urinary tract infection; diabetes; neurological disorder;
morbid obesity; current or attempted pregnancy; breastfeeding
or lactating; history of cancer, chemotherapy, or radiation ther-
apy; previous vaginal surgery or toning therapy;
vesicoureteral reflux; bladder calculi or tumor; or conservative
pelvic floor treatment (e.g., pelvic floor exercises, estrogen
cream) in the last 6 months.
Study device
Multimodal vaginal toning therapy is applied via an
intravaginal device (vSculpt, Joylux, Seattle, WA, USA) that
incorporates low-level light therapy in the red and near-
infrared wavelength spectrum (662–855 nm), heat (∼41 °C),
and therapeutic vibration (80–110 Hz; Fig. 1). Device settings
are individualized to comfort and include three light therapy
modes (6, 8, or 10 min) and six sonic vibration modes (con-
stant, wave, or pulse; each at high or low intensity). The sili-
cone device is inserted into the vaginal canal for up to 10 min
per treatment session. A water-based lubricant consisting of
water, glycol, and hydroxyethyl cellulose aids device insertion
and improves comfort, while augmenting the transfer of light
energy to the vaginal tissues.
Initial safety testing with the device was conducted in 20
women who were enrolled under common Institutional
Review Board approval, but who did not participate in the
longitudinal study described here. After 10 min of use, the
mean temperature at the surface of the device measured via
thermocoupling was 41.2 °C (range: 38.6° to 44.1 °C). All
values were below the 48.0 °C maximum allowed under the
International Standard for medical electrical equipment.
Additionally, no adverse events or visual changes in vaginal
tissue were noted.
Procedures
Each study participant underwent a routine examination by
the lead author or nurse practitioner to visually inspect the
vaginal tissue and evaluate pelvic floor muscle strength
(PFMS) using the Oxford Grading System where 0=no con-
traction, 1 = flicker, 2 =weak, 3 =moderate, 4 = good (with
lift), and 5= strong. A 1-h pad weight test (PWT) was per-
formed to determine the volume of urine leakage during 1 h of
standardized activities and exercises. Patients completed val-
idated QoL questionnaires related to urinary incontinence
symptoms and sexual function. Following completion of
baseline assessments, patients were instructed to use the de-
vice every other day for 45 days. During this period, patients
were instructed to maintain current lifestyle habits and to re-
frain from activities that may positively (e.g., pelvic floor
muscle training) or negatively (e.g., an increase in physical
activity) influence the study results. Following the treatment
period, patients returned to the clinic and all examinations and
questionnaires were repeated. Pelvic floor muscle strength at
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follow-up was assessed by the other rater, who was blinded to
the pre-treatment values. Device safety and patient satisfaction
were also assessed at the follow-up visit.
Outcomes
The primary endpoint of this study was change in the 1-h
PWT during the treatment period. In accordance with Food
and Drug Administration urinary incontinence study guid-
ance, treatment success was defined as PWT increase <1
g—values of 1–10, 11–50, and >50 g were classified as mild,
moderate, and severe respectively [14]. A clinically meaning-
ful level of improvement in pad weight was defined as >50%
reduction relative to baseline [15]. Incontinence-related QoL
was measured using the Urogenital Distress Inventory Short
Form (UDI-6), a six-item measure of urogenital distress, and
the Incontinence Impact Questionnaire-Short Form (IIQ-7), a
seven-item measure of incontinence impact [16]. Total scores
for UDI-6 and IIQ-7 were normalized to a 0 to 100 scale.
Sexual function was assessed with the Female Sexual
Function Index (FSFI) and Female Sexual Distress Scale-
Revised 2005 (FSDS-R) questionnaires. Values≤26.55 (pos-
sible score range: 2 to 36) for FSFI [17] and≥11 (possible
score range: 0 to 52) for FSDS-R [18] effectively discriminate
between women with and those without female sexual dys-
function. Patient satisfaction with vaginal toning therapy was
assessed on a five-point scale with possible responses
consisting of extremely satisfied, somewhat satisfied, neutral
(neither satisfied or dissatisfied), somewhat dissatisfied, and
extremely dissatisfied. Device safety was evaluated by deter-
mining the incidence of adverse events incurred at any point
during the study, regardless of severity, including discomfort
with device insertion or use, local tissue warmth, nerve tin-
gling, cramping, vaginal discharge, vaginal irritation, vaginal
infection, or vaginal sensitivity.
Data analysis
A sample size of 45 patients provided 90% statistical power to
detect pre-to-post effect size≥0.5 with a paired t test and two-
sided alpha=0.05. Continuous data were reported as mean
and standard deviation and categorical data were reported as
counts and percentages, unless otherwise specified. Paired t
test, Mann–Whitney U test, and Wilcoxon signed-rank tests
evaluated change in outcomes over the treatment period.
Binary logistic regression was performed to identify predic-
tors of patient satisfaction with vaginal toning therapy. Data




Between May 2016 and July 2016, consecutive patients were
screened for study eligibility. Reasons for study exclusion at
initial screening were nonvaginal birth (n=33), pregnant/
lactating (n=22), pre-existing exclusionary medical condi-
tions (n= 19), recent pelvic floor/vaginal therapy (n=15),
age <30 or >59 years (n=12), and current cancer treatment
(n=3). Ultimately, 55 patients were enrolled in the study
(comprising the safety population) and 48 patients completed
the study with adequate compliance (comprising the per-
protocol [PP] population). Five patients withdrew from the
study—4 for reasons unrelated to the study and 1 who report-
ed discomfort related to device warmth. Two patients were
excluded from analyses owing to poor (<30%) compliance.
Within the PP population, 38 patients had a positive 1-h PWT
at baseline (positive PWT population). Safety data are present-
ed for the safety population (n=55), 1-h PWT data are pre-
sented for the positive PWT population (n=38), and the re-
maining analyses are presented for the PP population (n=48).
Baseline patient characteristics
Mean patient age was 46±7 years (range: 32 to 59 years). All
women reported SUI—88% reported on the UDI-6 that SUI
symptom bother was moderate or great and 79% had a posi-
tive (>1 g) 1-h PWT. Pelvic floor muscle strength was low
overall—42% of patients were unable to elicit voluntary con-
traction (grade 0) and 42% elicited a flicker only (grade 1).
Regarding the inclusion criteria, all women reported painful
Fig. 1 vSculpt multimodal
vaginal toning therapy device
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and dissatisfying intercourse—most met the criteria for female
sexual dysfunction (Table 1).
Treatment compliance
Patients underwent 24±5 treatment sessions and returned for
follow-up at 50±11 days. Median treatment compliance, de-
fined as actual treatment sessions divided by anticipated treat-
ment sessions, was 96%.
One-hour pad weight test
Of the 48 patients, 38 (79%) had a positive 1-h PWT at base-
line (range: 3.5–63.8 g). Of these patients, urine leakage vol-
ume was classified as moderate or severe in 82% of patients at
baseline, but only in 18% after treatment. No leakage was
identified in 55% of patients after therapy. Treatment success,
defined as >50% improvement relative to baseline, was
achieved in 84% of patients. Median pad weight decreased
from 18 g (IQR: 13 to 30 g) at baseline to 0 g (IQR: 0 to
4 g) post-treatment (p<0.001).
Incontinence-related quality of life
UDI-6 total score improved in 92% of patients. Mean UDI-6
total score decreased 50% over the treatment period, from 53
±19 to 27±19 (p<0.001; Fig. 2). On the UDI-6 question
specific to SUI (bladder leakage related to physical activity,
sneezing, or coughing), the percentage of patients reporting
moderate or great symptom bother decreased from 88% at
baseline to 33% after therapy. IIQ-7 total score improved in
85% of patients. Mean IIQ-7 total score decreased 69% over
the treatment period, from 31 ± 22 to 10 ± 11 (p < 0.001;
Fig. 3).
Sexual function quality of life
The total FSDS-R score improved in 81% of patients. Mean
total FSDS-R score decreased 54% over the treatment period,
from 21±12 to 10±10 (p<0.001; Fig. 4). Total FSFI score
increased in 77% of patients. Mean total FSFI score increased
15% over the treatment period, from 25 ± 6 to 29 ± 6
(p<0.001; Fig. 5). The percentage of patients that met the
criteria for female sexual dysfunction before and after therapy
decreased from 81 to 31% with the FSDS-R and from 63 to
27% with the FSFI.
Quality of life sensitivity analysis
A sensitivity analysis was performed to evaluate the impact of
missing data on QoL outcomes. We performed a worst-case
analysis whereby in the 7 patients excluded from the PP pop-
ulation, we imputed final follow-up data using a baseline car-
ried forward approach—that is, assuming no improvement
from baseline. Even in this worst-case scenario, mean
Fig. 2 Change in Urinary Distress Inventory Short Form (UDI-6) total
score following vaginal toning therapy. Data are mean and 95%
confidence interval. ***p< 0.001 for pre-to-post change
Table 1 Baseline patient characteristics (n = 48)
Variable Value
Demographics











Prior vaginal surgery or laser treatment 0% (0/48)
Pelvic floor muscle strength
0 (no contraction) 42% (20/48)
1 (flicker) 42% (20/48)
2 (weak) 15% (7/48)
3 (moderate) 2% (1/48)
4 (good, with lift) 0
5 (strong) 0
Stress urinary incontinence symptoms






FSDS-R (total score ≥ 11) 81% (39/48)
FSFI (total score ≤ 26.55) 63% (30/48)
FSDS-R Female Sexual Distress Scale-R, FSFI Female Sexual Function
Index
a In 2 patients, value ≥ 1 , although exact number is unavailable
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improvements relative to baseline were 45% for UDI-6, 63%
for IIQ-7, 47% for FSDS-R, and 13% for FSFI (all p<0.001).
Therefore, the interpretation of device efficacy data is not
influenced by reporting PP population outcomes.
Pelvic floor muscle strength
Pelvic floor muscle strength significantly improved during the
course of the study (p<0.001). Strength improved by one
class in 43% of patients and by two classes in 11% of patients.
None of the patients experienced a decrease in PFMS. Patients
with the lowest baseline PFMS were most responsive to
therapy.
Patient satisfaction
Patient satisfaction, defined as a response of somewhat or
extremely satisfied with therapy, was 83%. The sole predictor
of patient satisfaction was the magnitude of relative improve-
ment in the UDI-6 total score (odds ratio=1.32 per 10% im-
provement, p=0.02). Post hoc assessment of these data iden-
tified a nonlinear threshold effect at a 25% relative improve-
ment on the UDI-6, that is, in patients with <25% improve-
ment in UDI-6 total score, satisfaction rates were 45% (5 out
of 11), whereas in patients with ≥25% improvement, satisfac-
tion rates were 95% (35 out of 37).
Adverse events
Of the 55 women enrolled in the study, 2 (3.6%) reported an
adverse event. One patient withdrew from the study owing to
self-reported excessive device warmth (previously described).
One urinary tract infection was reported in a patient who did
not properly sterilize the device after each use. The patient
discontinued use for 2 weeks until the infection resolved, then
resumed therapy and completed the study with no further is-
sues. No additional reports of discomfort with device insertion
or use, local tissue warmth, nerve tingling, cramping, vaginal
discharge, vaginal irritation, vaginal infection, or vaginal sen-
sitivity were observed at any time during the study.
Discussion
One in seven adult women undergo surgery for SUI during
their lifetime [19]. This statistic highlights the prevalence and
morbidity of SUI in addition to the failure of conservative
therapies to sufficiently resolve patient symptoms. The results
of this study demonstrate that multimodal vaginal toning ther-
apy is safe and effective in women with SUI, resulting in
statistically significant and clinically meaningful reductions
in bladder symptoms. Additionally, this therapy was associat-
ed with improvements in pelvic floor muscle strength and
QoL.
Post-partum SUI may manifest from damage to the fascia,
ligaments, pelvic floor muscles, and nerves supporting and
controlling the bladder neck and urethra. Pelvic floor muscle
weakness may increase the mobility of the bladder neck and
urethra, leading to urethral sphincter incompetence [20].
Changes in collagen tensile properties and total collagen con-
tent are common post-partum and may contribute to reduced
functional support of pelvic floor musculature [21]. Smooth
muscle inhibition, increased elastase activity in vaginal tissue,
and inflammatory processes are other factors known to con-
tribute to SUI risk post-partum [22].
Fig. 3 Change in Incontinence Impact Questionnaire-Short Form (IIQ-7)
total score following vaginal toning therapy. Data are mean and 95%
confidence interval. ***p< 0.001 for pre-to-post change
Fig. 4 Change in Female Sexual Distress Scale-Revised (FSDS-R) total
score following vaginal toning therapy. Data are mean and 95%
confidence interval. ***p< 0.001 for pre-to-post change
Fig. 5 Change in Female Sexual Function Index (FSFI) total score
following vaginal toning therapy. Data are mean and 95% confidence
interval. ***p < 0.001 for pre-to-post change
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Multimodal vaginal toning exerts therapeutic efficacy by
several distinct mechanisms of action. Low-level light energy
from light-emitting diodes (LEDs) at the right dosimetry pa-
rameters (wavelength, power density, time) produces photo-
chemical reactions that act on mitochondria [23] to increase
adenosine triphosphate production [24], in addition to the in-
duction of various transcription factors [25]. Ultimately, low-
level light energy increases protein synthesis and the modula-
tion of growth factors, inflammatory mediators, and in-
creased tissue oxygenation and repair [25]. The applica-
tion of heat has a two-fold effect on connective tissue. On
a macro-tissue level, heat increases circulation and me-
tabolism, whereas on a micro-tissue level, dimensional
changes are induced in the collagen molecule itself [26].
At tissue temperatures elicited by the device in this study
(40–42 °C), denaturing and reconfiguring of these bonds
occurs, which increases the elasticity and strength of col-
lagen fibers [27]. The key effects of vibration therapy on
connective tissue are related to fibroblasts, which are in-
tegrally involved in remodeling the extra-cellular matrix
(ECM) [28]. Two ECM glycoproteins, tenascin and col-
lagen XII, are specifically expressed in areas of high me-
chanical strain. Tenascin appears around healing wounds
and is part of the control response involving another pro-
tein important in collagen binding, fibronectin [29].
Vibration therapy takes advantage of the body’s reaction
to mechanical stress, a state in which higher levels of
tenascin and collagen XII are produced by fibroblasts at-
tached to strained collagen, compared with relaxed colla-
gen. Ultimately, the intravaginal application of low-level
light therapy, heat, and therapeutic vibration is thought to
improve incontinence symptoms and sexual function by
positive adaptations to connective tissue and ECM, in
addition to increasing micro-circulation and exerting
anti-inflammation properties [30].
Conservative therapy using electrical stimulation is an al-
ternative treatment option for women with SUI. Guralnick
et al. [31] reported the results of a 3-month study in women
with urinary incontinence who were treated using an
intravaginal device that provides electrical stimulation and
biofeedback. Median improvements over a 3-month follow-
up were 90% on the 24-h PWT, 40% for UDI-6, and 60% for
IIQ-7, which are comparable to the results of the current study.
However, the incidence of infection-related complications
was much higher in the study by Guralnick et al., at 32% (9
out of 28) compared with 2% (1 out of 55) in the current study.
Also, events related to device discomfort consisted of electri-
cal shock sensations in 7% of patients treated with electrical
stimulation versus a single report of excessive warmth (2%) in
the current study. Other studies have reported positive results
in patients with urinary incontinence, with acceptable safety
outcomes using an Er:YAG laser; however, this treatment is
considerably more expensive than self-administered
alternatives because in-office, physician-administered treat-
ments are required. Fractional microablative CO2 laser and
radiofrequency thermal therapy are promising non-invasive
alternatives for symptoms related to vulvovaginal atrophy or
vaginal laxity; however, research into these therapies for uri-
nary incontinence is scarce and the need for in-office,
physician-administered treatments similarly contributes to
higher costs.
Several limitations to this study should be noted. First, this
prospective study did not utilize a control group. Although
case series that utilize patient-reported outcomes are suscepti-
ble to placebo effects, the 1-h PWT is an objective standard-
ized test that is less prone to such biases. Additionally, the
magnitude of the treatment effects observed with urinary in-
continence and sexual function questionnaire scores was
greater than that reasonably expected because of the placebo
effect. Specifically, the effect size was >1.0 for UDI-6, IIQ-7,
and FSDS-R, which is interpreted as a very large treatment
benefit. The effect size for FSFI was >0.6, which is a
moderate-to-large treatment benefit. Second, baseline patient
characteristics that may influence urinary incontinence symp-
toms, such as physical activity levels, diet, and fluid intake,
were not collected. Despite this limitation, the fact that pa-
tients maintained their current lifestyle during the study may
somewhat mitigate the influence of confounding variables.
Finally, device usage was evaluated over approximately
7 weeks in the current study. Clinical evaluation of long-
term treatment outcomes is warranted.
In conclusion, multimodal vaginal toning therapy is safe
and results in statistically significant and clinically meaningful
improvements in bladder symptoms, pelvic floor muscle
strength, and QoL in women with SUI.
Acknowledgements The authors thank the subjects whose participa-
tion made this study possible and Dr Peggy Hutchinson of Seattle OB/
GYN for assistance in facilitating the clinical study. This study was sup-
ported by Joylux, Inc.
Compliance with ethical standards
Conflicts of interest Sarah de la Torre and Larry Miller disclose con-
sultancy with Joylux, Inc. Sarah de la Torre discloses receiving research
funds from Joylux, Inc., for the conduction of this study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
Int Urogynecol J
References
1. Morrison A, Levy R. Fraction of nursing home admissions attrib-
utable to urinary incontinence. Value Health. 2006;9(4):272–4.
doi:10.1111/j.1524-4733.2006.00109.x.
2. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary
incontinence in women in four European countries. BJU Int.
2004;93(3):324–30.
3. Fatton B, de Tayrac R, Costa P. Stress urinary incontinence and
LUTS in women–effects on sexual function. Nat Rev Urol.
2014;11(10):565–78. doi:10.1038/nrurol.2014.205.
4. BirnbaumH, Leong S, Kabra A. Lifetimemedical costs for women:
cardiovascular disease, diabetes, and stress urinary incontinence.
Womens Health Issues. 2003;13(6):204–13.
5. Kinchen KS, Long S, Orsini L, Crown W, Swindle R. A retrospec-
tive claims analysis of the direct costs of stress urinary incontinence.
Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(6):403–11.
doi:10.1007/s00192-003-1096-6.
6. Harris SS, Link CL, Tennstedt SL, Kusek JW, McKinlay JB. Care
seeking and treatment for urinary incontinence in a diverse popula-
tion. J Urol. 2007;177(2):680–4. doi:10.1016/j.juro.2006.09.045.
7. Richter HE, Burgio KL, Brubaker L, Nygaard IE, Ye W, Weidner
A, et al. Continence pessary compared with behavioral therapy or
combined therapy for stress incontinence: a randomized controlled
trial. Obstet Gynecol. 2010;115(3):609–17. doi:10.1097/AOG.0
b013e3181d055d4.
8. Nitti VW. Complications of midurethral slings and their manage-
ment. Can Urol Assoc J. 2012;6(5 Suppl 2):S120–22. doi:10.5489
/cuaj.12197.
9. Hansen MF, Lose G, Kesmodel US, Gradel KO. Repeat surgery
after failed midurethral slings: a nationwide cohort study, 1998–
2007. Int Urogynecol J. 2016;27(7):1013–9. doi:10.1007/s00192-
015-2925-0.
10. Stav K, Dwyer PL, Rosamilia A, Schierlitz L, Lim YN, Chao F,
et al. Repeat synthetic mid urethral sling procedure for women with
recurrent stress urinary incontinence. J Urol. 2010;183(1):241–6.
doi:10.1016/j.juro.2009.08.111.
11. Tuncer M, Tarhan F, Kafkasli A, Demir K, Yucetas U, Faydaci G,
et al. The effects of stress incontinence surgery on sexual function
and life quality of women. Arch Ital Urol Androl. 2016;88(2):106–
10. doi:10.4081/aiua.2016.2.106.
12. Lim R, LiongML, LeongWS, KhanNA, Yuen KH. Effect of stress
urinary incontinence on the sexual function of couples and the
quality of life of patients. J Urol. 2016;196(1):153–8. doi:10.1016
/j.juro.2016.01.090.
13. Committee on Practice Bulletins, American Urogynecologic
Society. ACOG practice bulletin no. 155 summary: urinary incon-
tinence in women. Obstet Gynecol. 2015;126(5):1120–2.
doi:10.1097/AOG.0000000000001143.
14. Klarskov P, Hald T. Reproducibility and reliability of urinary incon-
tinence assessment with a 60 min test. Scand J Urol Nephrol.
1984;18(4):293–8.
15. Food and Drug Administration (2011) Guidance for Industry and
Food and Drug Administration staff: Clinical investigations of de-
vices indicated for the treatment of urinary incontinence.
h t t p : / / w w w . f d a . g o v / R e g u l a t o r y I n f o r m a t i o n /
Guidances/ucm070852.htm. Accessed 27 September 2016
16. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA.
Short forms to assess life quality and symptom distress for urinary
incontinence in women: the Incontinence Impact Questionnaire and
the Urogenital Distress Inventory. Continence Program for Women
Research Group. Neurourol Urodyn. 1995;14(2):131–9.
17. Wiegel M, Meston C, Rosen R. The female sexual function index
(FSFI): cross-validation and development of clinical cutoff scores. J
S ex Ma r i t a l Th e r. 2 005 ; 31 ( 1 ) : 1–20 . d o i : 10 . 1080
/00926230590475206.
18. Derogatis L, ClaytonA, Lewis-D’Agostino D,Wunderlich G, Fu Y.
Validation of the female sexual distress scale-revised for assessing
distress in women with hypoactive sexual desire disorder. J Sex
Med. 2008;5(2):357–64. doi:10.1111/j.1743-6109.2007.00672.x.
19. Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M.
Lifetime risk of stress urinary incontinence or pelvic organ prolapse
surgery. Obstet Gynecol. 2014;123(6):1201–6. doi:10.1097
/AOG.0000000000000286.
20. Davis K, Kumar D. Pelvic floor dysfunction: a conceptual frame-
work for collaborative patient-centred care. J Adv Nurs.
2003;43(6):555–68.
21. Chaliha C, Kalia V, Stanton SL, Monga A, Sultan AH. Antenatal
prediction of postpartum urinary and fecal incontinence. Obstet
Gynecol. 1999;94(5 Pt 1):689–94.
22. Chen B,Wen Y, Yu X, Polan ML. The role of neutrophil elastase in
elastin metabolism of pelvic tissues fromwomenwith stress urinary
incontinence. Neurourol Urodyn. 2007;26(2):274–9. doi:10.1002
/nau.20347.
23. Greco M, Guida G, Perlino E, Marra E, Quagliariello E. Increase in
RNA and protein synthesis bymitochondria irradiated with helium-
neon laser. Biochem Biophys Res Commun. 1989;163(3):1428–34.
24. Karu T. Primary and secondary mechanisms of action of visible to
near-IR radiation on cells. J Photochem Photobiol B. 1999;49(1):1–
17. doi:10.1016/S1011-1344(98)00219-X.
25. Chen AC, Arany PR, Huang YY, Tomkinson EM, Sharma SK,
Kharkwal GB, et al. Low-level laser therapy activates NF-kB via
generation of reactive oxygen species in mouse embryonic fibro-
blasts. PLoS One. 2011;6(7):e22453. doi:10.1371/journal.
pone.0022453.
26. Rigby BJ. The effect of mechanical extension upon the thermal
stability of collagen. Biochim Biophys Acta. 1964;79:634–6.
27. Peacock Jr EE. Some biochemical and biophysical aspects of joint
stiffness: role of collagen synthesis as opposed to altered molecular
bonding. Ann Surg. 1966;164(1):1–12.
28. Chiquet M, Matthisson M, Koch M, Tannheimer M, Chiquet-
Ehrismann R. Regulation of extracellular matrix synthesis by me-
chanical stress. Biochem Cell Biol. 1996;74(6):737–44.
29. Tracy LE, Minasian RA, Caterson EJ. Extracellular matrix and
dermal fibroblast function in the healing wound. Adv Wound
Care (New Rochelle). 2016;5(3):119–36. doi:10.1089
/wound.2014.0561.
30. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, HamblinMR.
The nuts and bolts of low-level laser (light) therapy. Ann Biomed
Eng. 2012;40(2):516–33. doi:10.1007/s10439-011-0454-7.
31. Guralnick ML, Kelly H, Engelke H, Koduri S, O’Connor RC.
InTone: a novel pelvic floor rehabilitation device for urinary incon-
tinence. Int Urogynecol J. 2015;26(1):99–106. doi:10.1007
/s00192-014-2476-9.
Int Urogynecol J
